Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,733
  • Shares Outstanding, K 71,110
  • Annual Sales, $ 570 K
  • Annual Income, $ -26,430 K
  • EBIT $ -57 M
  • EBITDA $ -56 M
  • 60-Month Beta 0.13
  • Price/Sales 46.23
  • Price/Cash Flow N/A
  • Price/Book 0.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings $-0.14 on 05/13/25
  • Next Earnings Date 08/12/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 523.27% ( +445.65%)
  • Historical Volatility 108.84%
  • IV Percentile 59%
  • IV Rank 36.35%
  • IV High 1,303.49% on 06/17/25
  • IV Low 77.61% on 07/15/25
  • Put/Call Vol Ratio 0.02
  • Today's Volume 49
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 889
  • Open Int (30-Day) 829

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.16
  • Number of Estimates 5
  • High Estimate -0.14
  • Low Estimate -0.18
  • Prior Year 0.12
  • Growth Rate Est. (year over year) -233.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2851 +68.12%
on 06/18/25
0.6100 -21.43%
on 07/17/25
+0.1769 (+58.50%)
since 06/17/25
3-Month
0.2650 +80.87%
on 04/21/25
0.6100 -21.43%
on 07/17/25
+0.1907 (+66.08%)
since 04/17/25
52-Week
0.2425 +97.65%
on 04/09/25
1.4700 -67.39%
on 11/11/24
-0.5407 (-53.01%)
since 07/17/24

Most Recent Stories

More News
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

OVID : 0.4793 (+22.90%)
Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?

These two names could be long-term biotech plays for those willing to take the high-risk road.

$SPX : 6,297.36 (+0.54%)
OVID : 0.4793 (+22.90%)
NUVB : 2.24 (+0.45%)
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

OVID : 0.4793 (+22.90%)
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

OVID : 0.4793 (+22.90%)
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

OVID : 0.4793 (+22.90%)
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

OVID : 0.4793 (+22.90%)
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

OVID : 0.4793 (+22.90%)
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

OVID : 0.4793 (+22.90%)
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

OVID : 0.4793 (+22.90%)
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

OVID : 0.4793 (+22.90%)

Business Summary

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved...

See More

Key Turning Points

3rd Resistance Point 0.7895
2nd Resistance Point 0.6998
1st Resistance Point 0.5895
Last Price 0.4793
1st Support Level 0.3895
2nd Support Level 0.2998
3rd Support Level 0.1895

See More

52-Week High 1.4700
Fibonacci 61.8% 1.0011
Fibonacci 50% 0.8563
Fibonacci 38.2% 0.7114
Last Price 0.4793
52-Week Low 0.2425

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar